natgillin/translations-raw huggingface dataset:
The reduction in incidence of colectomy was also examined in another randomised, double-blind study (C0168Y06) in hospitalised patients (n = 45) with moderately to severely active ulcerative colitis who failed to respond to IV corticosteroids and who were therefore at higher risk for colectomy.
Zmanjšanje incidence kolektomij so proučevali še v eni randomizirani, dvojno slepi študiji (C0168Y06) pri hospitaliziranih bolnikih (n = 45) z zmerno do močno aktivnim ulceroznim kolitisom, ki se niso odzvali na zdravljenje z intravenskimi kortikosteroidi in so imeli zato večje tveganje, da bo pri njih potrebna kolektomija.
The reduction in incidence of colectomy was also examined in another randomised, double-blind study (C0168Y06) in hospitalised patients (n=45) with moderately to severely active ulcerative colitis who failed to respond to intravenous (IV) corticosteroids and who were therefore at higher risk for colectomy.
Zmanjšanje incidence kolektomij so proučevali še v eni randomizirani, dvojno slepi študiji (C0168Y06) pri hospitaliziranih bolnikih (n = 45) z zmerno do močno aktivnim ulceroznim kolitisom, ki se niso odzvali na zdravljenje z intravenskimi (i.v.) kortikosteroidi in so imeli zato večje tveganje, da bo pri njih potrebna kolektomija.
The reduction in incidence of colectomy was also examined in another randomised, double-blind study (C0168Y06) in hospitalised patients (n=45) with moderately to severely active ulcerative colitis who failed to respond to IV corticosteroids and who were therefore at higher risk for colectomy.
Zmanjšanje incidence kolektomij so proučevali še v eni randomizirani, dvojno slepi študiji (C0168Y06) pri hospitaliziranih bolnikih (n = 45) z zmerno do močno aktivnim ulceroznim kolitisom, ki se niso odzvali na zdravljenje z intravenskimi kortikosteroidi in so imeli zato večje tveganje, da bo pri njih potrebna kolektomija.
The reduction in PTH levels also leads to a decrease in blood calcium levels.
Zmanjšanje ravni paratiroidnega hormona nato privede do znižanja ravni kalcija v krvi.
The reduction in risk for a vomiting episode over the 0 to 24 hour period with aprepitant 40 mg relative to ondansetron 4 mg was 53.3 % (95 % C.I.: 35.3 to 66.3) in an analysis that censors patients at the time of rescue use.
Znižanje tveganja za epizodo bruhanja v času 0-24 ur z aprepitantom 40 mg glede na ondansetron 4 mg je bilo 53,3 % (95-odstotni IZ: 35,3 do 66,3) v analizi, ki nadzoruje bolnike v času rešilnega zdravljenja.
The reduction in severe asthma attacks and consequent need for hospital treatment was considered important and outweighed the low risk of side effects, since the medicine’s safety profile raised no major concerns.
Zmanjšanje napadov hude astme in posledično manjšo potrebo po bolnišničnem zdravljenju so ocenili za pomembna in sta odtehtala majhno tveganje za neželene učinke, saj varnostni profil zdravila ni vzbudil večjih skrbi.
The reduction in systemic clearance estimated by population PK modelling for patients at the midpoints of the renal impairment categories relative to patients with median creatinine clearance in the PK population (79.9 ml/min) were 1.4% for mild (75 ml/min), 11.7% for moderate (45 ml/min) and 24.0% for severe (22.5 ml/min) renal impairment.
Zmanjšanje sistemskega očistka, ocenjeno s populacijskim farmakokinetičnim modeliranjem za bolnike na srednji točki kategorije okvare ledvic glede na bolnike z medianim očistkom kreatinina v farmakokinetični populaciji (79,9 ml/min), je bilo 1,4 % pri blagi (75 ml/min), 11,7 % pri zmerni (45 ml/min) in 24,0 % pri hudi (22,5 ml/min) okvari ledvic.
The reduction in the level of sex hormones also allows the liver to cleanse the pig’s system of skatole more effectively, reducing its levels in the body.
Zmanjšanje ravni spolnih hormonov prav tako omogoča, da jetra iz sistema prašiča bolj učinkovito izčistijo skatol, s tem pa se zniža njegova raven v telesu.
The reduction to a putative amine, as well as the subsequent N-acetylation, occurs to a minor extent.
Redukcija v domnevni amin se tako kot posledična N- acetilacija pojavi v manjšem obsegu.
the reductions in etravirine
farmakokinetičnih
The reductions in HbA1c and superiority vs sitagliptin observed after 26 weeks of liraglutide treatment (1.2 mg and 1.8 mg) were sustained after 52 weeks of treatment (­1.29% and ­1.51% vs ­0.88%, p0.0001).
Znižanje HbA1c in superiornost v primerjavi s sitagliptinom, opažena po 26 tednih zdravljenja z liraglutidom (1,2 mg in 1,8 mg), sta se ohranila tudi po 52 tednih zdravljenja (-1,29 % in -1,51 % v prim. z -0,88 %, p  0,0001).
The reductions in RTG led to increased UGE in subjects with type 2 diabetes treated with either 100 mg or 300 mg of canagliflozin ranging from 77 g/day to 119 g/day across the phase 1 studies; the UGE observed translates to a loss of
V vseh študijah faze I je pri bolnikih s sladkorno boleznijo tipa 2, ki so prejemali kanagliflozin bodisi v odmerku 100 mg ali 300 mg, znižanje praga za izločanje glukoze povzročilo povečano izločanje glukoze z urinom, ki je znašalo od 77 g/dan do 119 g/dan.
The reductions with Lyxumia ranged from 4.51 to 7.96 mmol/L (81.2 to 143.3 mg/dl) from baseline at the end of the main 24-week treatment period across all studies in which post-prandial glucose was measured; 26.2% to 46.8% of patients had a 2-hour post-prandial glucose value below 7.8 mmol/L (140.4 mg/dl).
Znižanja od izhodišča so bila na koncu glavnega 24-tedenskega obdobja zdravljenja z zdravilom Lyxumia v razponu od 4,51 do 7,96 mmol/l (81,2 do 143,3 mg/dl) v vseh študijah, v katerih so merili postprandialno glukozo; od 26,2 % do 46,8 % bolnikov je imelo postprandialno glukozo po 2 urah pod 7,8 mmol/l (140,4 mg/dl).
The reference medicine for Bemfola is GONAL-f.
Referenčno zdravilo za zdravilo Bemfola je zdravilo GONAL-f.
The reference medicine for Omnitrope is Genotropin.
Referenčno zdravilo za Omnitrope je Genotropin.
The reference medicine for Ovaleap is GONAL-f.
Referenčno zdravilo za zdravilo Ovaleap je zdravilo GONAL-f.
The reference medicine for Remsima is Remicade.
Referenčno zdravilo za zdravilo Remsima je Remicade.
The reference medicine for Zyclara is Aldara, which contains imiquimod at 5% strength.
Referenčno zdravilo za zdravilo Zyclara je Aldara, ki vsebuje 5 % imikvimoda.
The regimen 3 mg/kg/day during 6 months (selected at the end of the phase II part of the study) presented 60.4% of success versus 3.6% in the placebo arm (p value < 0.0001).
Režim 3 mg/kg/dan v 6 mesecih (izbran ob koncu II. faze študije) je bil uspešen v 60,4 % v primerjavi s 3,6-odstotnim uspehom pri placebu (vrednost p < 0,0001).
The regimen administered should be selected based on the anticipated efficacy and safety of the combination treatment for an individual patient (see section 5.1).
Izbira terapevtske sheme pa mora temeljiti na pričakovani učinkovitosti in varnosti kombinirane terapije za vsakega posameznega bolnika (glejte poglavje 5.1).
The registry is planned to be continued until at least 70 patients are recruited on Firdapse and followed for up to five years, with a minimum of at least three years for the last subject recruited to the registry.
Dopolnjevanje registra naj bi se nadaljevalo, dokler ne bo vanj vključenih vsaj 70 bolnikov, ki prejemajo zdravilo Firdapse, in dokler ne bodo ti spremljani do pet let, pri čemer morajo od vključitve zadnjega preiskovanca v register preteči najmanj tri leta.
The registry should collect data from both patients
Register bo zbiral podatke bolnikov in zdravnikov.
The registry will monitor accumulating data on efficacy and safety in the treatment of inborn errors in primary bile acid synthesis in infants, children, adolescents and adults due to Sterol 27-hydroxylase (presenting as cerebrotendinous xanthomatosis, CTX), 2- (or α-) methylacyl-CoA racemase (AMACR) and Cholesterol 7α- hydroxylase (CYP7A1) deficiencies.
Z registrom se bodo spremljali kumulativni podatki o učinkovitosti in varnosti pri zdravljenju prirojenih okvar sinteze primarnih žolčnih kislin pri dojenčkih, otrocih, mladostnikih in odraslih zaradi pomanjkanja sterol 27- hidroksilaze (ki se kaže kot cerebrotendinozna ksantomatoza, CTX), 2- (ali α-) metilacil-CoA racemaze (AMACR) in holesterol 7α-hidroksilaze (CYP7A1).
The reinstitution or withholding of Bronchitol following smaller episodes of haemoptysis should be based on clinical judgement.
O ponovni uvedbi ali zadržanju zdravila Bronchitol po manjših epizodah hemoptize presodi zdravnik.
The relationship between in vitro anti-HIV-1 activity of amprenavir and the inhibition of HIV-1 replication in humans has not been defined.
Povezava med proti- HIV-1 aktivnostjo amprenavirja in vitro in inhibicijo replikacije HIV-1 pri človeku ni bila določena.
The relationship between rivaroxaban concentration and factor-Xa activity was best described by an Emax model.
Razmerje med koncentracijo rivaroksabana in aktivnostjo faktorja Xa je najbolje opisana z modelom Emax.
The relationship between tacrolimus trough levels (C24) and systemic exposure (AUC0-24) for Envarsus is similar to that of immediate- release tacrolimus.
Razmerje med najnižjimi vrednostmi takrolimusa (C24) in povprečni sistemski izpostavljenosti (AUC0-24) za zdravilo Envarsus je podobno kot pri takrolimusu s takojšnjim sproščanjem.
The relationship to Thyrogen administration is unknown.
Povezanost z dajanjem zdravila Thyrogen ni znana.
The relationship, if any, between receptor tyrosine kinase (RTK) inhibition and cardiac function remains unclear.
Povezava med zaviranjem receptorjev tirozin-kinaze (RTK) in delovanjem srca ostaja nejasna, v kolikor sploh obstaja.
The relative benefit of combination therapy with Viraferon + ribavirin is particularly significant in the most difficult to treat subgroup of patients (genotype 1 and high virus load) (Table 3).
Viraferon in ribavirinom je še posebej pomembna za podskupino bolnikov, ki jih je najtežje zdraviti (genotip 1 in velika virusna obremenitev) (Preglednica 3).
The relative bioavailability of nevirapine when dosed as one 400 mg Viramune prolonged-release tablet, relative to two 200 mg Viramune immediate- release tablets, was approximately 75 %.
Relativna biološka uporabnost nevirapina je bila po eni 400 mg tableti zdravila Viramune s podaljšanim sproščanjem, v primerjavi z dvema 200 mg tabletama zdravila Viramune s takojšnjim sproščanjem približno 75-odstotna.
The relative contribution of the inhibitors to inactivation of reteplase decreases as follows: C1-inactivator > 2- antiplasmin > 2-antitrypsin.
Relativni prispevki zaviralcev k inaktivaciji reteplaze se nižajo v naslednjem vrstnem redu: C1- inaktivator > α2-antiplazmin > α2-antitripsin.
The relative contribution of the metabolite to the pharmacological effect is estimated to be approximately 40%.
Relativni doprinos presnovka k farmakološkem učinku je ocenjen na približno 40%.
The relative contributions of previous placebo treatment in the double-blind phase and of other medications started during the open- label extension period are unknown.
Relativni prispevek predhodnega zdravljenja s placebom v dvojno slepi fazi in druga zdravila, uvedena v obdobju odprtega podaljška, niso znani.
The relative differences in the pharmacodynamic properties (GIRmax,AUCGIR, 0-120 min) between insulin aspart and human insulin in the elderly were similar to those seen in healthy subjects and in younger patients with diabetes.
Relativne razlike v farmakodinamičnih lastnostih (GIRmax, AUCGIR, 0-120 min) insulina aspart in humanega insulina so se pri starejših skladale s tistimi, ki so bile ugotovljene pri zdravih preiskovancih in mlajših bolnikih s sladkorno boleznijo.
The relative proportions of vemurafenib and its metabolites were characterised in a human mass balance study with a single dose of 14C-labeled vemurafenib administered orally.
Sorazmerne deleže vemurafeniba in njegovih presnovkov so določili v raziskavi masnega ravnovesja pri človeku z enkratnim odmerkom s 14C označenega vemurafeniba, dajanega peroralno.
The relative rate of ADPKD-related events was decreased by 13.5% in tolvaptan-treated patients, (hazard ratio, 0.87; 95% CI, 0.78 to 0.97; p=0.0095).
Relativna stopnja dogodkov, povezanih z ADPKD, se je pri bolnikih, zdravljenih s tolvaptanom, zmanjšala za 13,5 % (razmerje tveganja, 0,87; 95-% IZ, 0,78 do 0,97; p = 0,0095).
The relative rate reduction indicates how much the incidence of IPD in children of ≤5 years of age was reduced in the Synflorix cohort (followed for 3 years after NIP introduction) versus age and season matched non-vaccinated historical cohorts (each followed for 3 year periods before introduction of Synflorix into NIP).
Relativno zmanjšanje deleža kaže, koliko se je zmanjšala incidenca invazivne pnevmokokne bolezni pri otrocih v starosti ≤ 5 let v kohorti s cepivom Synflorix (spremljani 3 leta po uvedbi NPC) v primerjavi z necepljenima historičnima kohortama, usklajenima po starosti in sezoni (obe spremljani 3 leta pred uvedbo cepiva Synflorix v NPC).
The relative risk compared to placebo for a similar composite endpoint (CV death, MI, stroke) was 1.14 (95% CI 0.61 - 2.12) with celecoxib 200 mg twice daily.
Relativno tveganje za podoben sestavljeni opazovani dogodek (srčnožilna smrt, miokardni infarkt, možganska kap) je bilo za celekoksib 200 mg dvakrat na dan v primerjavi s placebom 1,14 (95 % IZ: 0,61–2,12).
The relative risk of venous thromboembolic events observed during raloxifene treatment was 1.60 (CI 0.95, 2.71) when compared to placebo, and was 1.0 (CI 0.3, 6.2) when compared to oestrogen or hormonal replacement therapy.
Relativno tveganje za venske tromboembolične zaplete, ki so jih ugotovili med zdravljenjem z raloksifenom, je bilo RR 1,60 (CI 0,95, 2,71) v primerjavi s placebom, in RR 1,0 (95 % CI 0,3–6,2) v primerjavi z estrogensko ali hormonsko nadomestno terapijo.
The relative selectivity of vernakalant on atrial versus ventricular refractoriness is postulated to result from the block of currents that are expressed in the atria, but not in the ventricles, as well as the unique electrophysiologic condition of the fibrillating atria.
Sorazmerna selektivnost vernakalanta za refraktarnost preddvorov v primerjavi s prekati naj bi bila posledica blokade tokov, ki so izraženi v preddvorih, ne pa v prekatih, pa tudi edinstvenega elektrofiziološkega stanja v preddvorih med fibrilacijo.
The relative treatment effect of ALIMTA was internally consistent across subgroups (including disease stage, induction response, ECOG PS, smoking status, gender, histology and age) and similar to that observed in the unadjusted OS and PFS analyses.
Relativni učinek zdravljenja z zdravilom ALIMTA je bil notranje konsistenten med podskupinami (vključno s stopnjo bolezni, odzivom na indukcijsko zdravljenje, stanjem zmogljivosti po ECOG, kajenjem, spolom, histologijo in starostjo) in podoben tistemu, ki so ga opazili pri neprilagojenih analizah skupnega preživetja in analizah preživetja brez napredovanja bolezni.
The relative treatment effect of ALIMTA was internally consistent across subgroups (including disease stage, induction response, ECOG PS, smoking status, gender, histology and age) and similar to that observed in the unadjusted OS and PFS analyses.
Relativni učinek zdravljenja z zdravilom ALIMTA je bil notranje konsistenten med podskupinami (vključno s stopnjo bolezni, odzivom na indukcijsko zdravljenje, stanjem zmogljivosti po ECOG, kajenjem, spolom, histologijo in starostjo) in podoben tistemu, ki so ga opazili pri neprilagojenih analizah skupnega preživetja in preživetja brez napredovanja bolezni.
The relative treatment effect of pemetrexed was internally consistent across subgroups (including disease stage, induction response, ECOG PS, smoking status, gender, histology and age) and similar to that observed in the unadjusted OS and PFS analyses.
Relativni učinek zdravljenja s pemetreksedom je bil notranje konsistenten med podskupinami (vključno s stopnjo bolezni, odzivom na indukcijsko zdravljenje, stanjem zmogljivosti po ECOG, kajenjem, spolom, histologijo in starostjo) in podoben tistemu, ki so ga opazili pri neprilagojenih analiz napredovanja bolezni.
The relative treatment effect of pemetrexed was internally consistent across subgroups (including disease stage, induction response, ECOG PS, smoking status, gender, histology and age) and similar to that observed in the unadjusted OS and PFS analyses.
Relativni učinek zdravljenja s pemetreksedom je bil notranje konsistenten med podskupinami (vključno s stopnjo bolezni, odzivom na indukcijsko zdravljenje, stanjem zmogljivosti po ECOG, kajenjem, spolom, histologijo in starostjo) in podoben tistemu, ki so ga opazili pri neprilagojenih analizah skupnega preživetja in analizah preživetja brez napredovanja bolezni.
The relatively fast absorption of soluble insulin ensures a constant supply of insulin to the blood from a relatively small pool under the skin.
Razmeroma hitra absorpcija topnega insulina zagotavlja stalen dotok insulina v kri iz razmeroma majhne kolicine pod kožo.
The release liner is removed prior to application.
Prevleko plasti, iz katere se sprošča zdravilna učinkovina, pred namestitvijo obliža odstranimo.
The release of tumour cell contents (tumour lysis syndrome), which may put extra stress on your body.
Sproščanje vsebine tumorskih celic (sindrom tumorske lize), ki lahko telo še dodatno obremeni.
The relevance of these findings in humans is unknown.
Pomen teh ugotovitev za ljudi ni znan.
The relevance of these findings to human risk is unknown.
Pomen teh ugotovitev za ljudi ni znan.
The relevance of these results to humans greater than 6 years of age is unknown.
Pomen teh rezultatov za ljudi, starejše od 6 let, ni znan.
The relevance of this finding for the therapeutic use in patients can not be excluded.
Pomembnosti te ugotovitve za terapevtsko uporabo pri bolnikih ni mogoče izključiti.
The remaining 10 subjects had insufficient platelet response to prior therapies.
Pri preostalih 10 preiskovancih pri predhodnih zdravljenjih ni prišlo do zadostnega odziva glede povečanja števila trombocitov.
The remaining 5 patients showed no significant change in motor development beyond Week 52 (with individual patient treatment durations ranging from 104 to 168 weeks; mean follow-up period of 140 weeks), including 4 patients with no significant motor skills in any of the positions evaluated and 1 patient with only functional sitting skills by the last study visit.
Preostalih 5 bolnikov ni pokazalo nobenih bistvenih sprememb glede motoričnega razvoja po tednu (s trajanjem zdravljenja pri posameznih bolnikih v razponu od 104 do 168 tednov; povprečno obdobje sledenja 140 tednov), vključno s 4 bolniki, ki niso imeli nobenih bistvenih motoričnih sposobnosti v nobenem od ocenjevanih stanj in 1 bolnikom, ki je imel le funkcionalno sposobnost sedenja do zadnjega obiska v študiji.
The remaining 5% represents metabolites below quantifiable concentrations.
Preostalih 5 % so presnovki pod količinsko opredeljivimi koncentracijami.
The remaining effects can be treated by your doctor if they persist.
Preostale učinke, če ne izginejo, lahko zdravi vaš zdravnik.
The remaining parts of a divided dispersible tablet can be stored at room temperature and should be used within 7 days.
Preostale dele razdeljene disperzibilne tablete lahko hranite pri sobni temperaturi in jih porabite v 7 dneh.
The remaining patients were treated with 2000 or 2500 U/m2 administered intramuscularly or intravenously.
Druge bolnike so zdravili z 2.000 ali 2.500 enot/m2 intramuskularno ali intravensko.
The remaining single-dose containers should be kept in the aluminium pouch.
Preostale enoodmerne vsebnike shranjujte v aluminijastem mošnjičku.
The remaining Water for Injections in the solvent vial after withdrawal of the 1.1 ml required for reconstitution has to be discarded
Preostanek vode za injekcije v viali z vehiklom je po odvzemu 1,1 ml, potrebnega za rekonstitucijo, treba zavreči
The removable needle cap of this pre-filled syringe contains a derivative of natural rubber latex.
Snemljiva zaporka na igli te napolnjene injekcijske brizge vsebuje derivat naravne lateksne gume.
The removal of NexoBrid and of dissolved eschar
Odstranitev zdravila NexoBrid in odpuščenih eshar
The renal clearance of zoledronic acid was correlated with creatinine clearance, renal clearance representing 75 ± 33 % of the creatinine clearance, which showed a mean of 84 ± 29 ml/min (range 22 to 143 ml/min) in the 64 cancer patients studied.
Ledvični očistek zoledronske kisline je bil postavljen v soodnosnost z očistkom kreatinina, ledvični očistek je predstavljal 75  33 % očistka kreatinina, ki je pri 64 proučevanih bolnikih z rakom kazal povprečje 84  29 ml/min (razpon od 22 do 143 ml/min).
The renal elimination of intact Cosentyx, an IgG monoclonal antibody, is expected to be low and of minor importance.
Nespremenjeno zdravilo Cosentyx, torej monoklonsko protitelo IgG, naj bi se po pričakovanjih izločalo skozi ledvice v majhnem obsegu in tako ledvično izločanje nima velikega pomena.
The renal elimination rate of memantine under alkaline urine conditions may be reduced by a factor of 7 to 9 (see section 4.4).
Pri alkalnem urinu lahko pride do zmanjšane hitrosti izločanja memantina za 7- do 9-krat (glejte poglavje 4.4).
The renal elimination rate of memantine under alkaline urine conditions may be reduced by a factor of 7 to9 (see section 4.4).
V primeru alkalnega urina lahko pride do zmanjšane hitrosti izločanja memantina za faktor 7 do 9 (glejte poglavje 4.4).
The renal function of these patients should be closely monitored with a frequency tailored to the individual patient’s medical condition.
Ledvično funkcijo se mora pri teh bolnikih skrbno nadzorovati in prilagoditi pogostnost nadzora zdravstvenemu stanju posameznega bolnika.
The renal function should also be assessed at least once a year in patients treated with Pradaxa or more frequently as needed in certain clinical situations when it is suspected that the renal function could decline or deteriorate (such as hypovolemia, dehydration, and with certain comedications, etc) (see sections 4.3, 4.4 and 5.2).
Pri nekaterih kliničnih stanjih je treba ledvično delovanje oceniti tudi med zdravljenjem, če obstaja sum, da je zmanjšano ali poslabšano (na primer pri hipovolemiji, dehidraciji in med sočasnim zdravljenjem z nekaterimi zdravili itd), (glejte poglavja 4.3, 4.4 in 5.2).
The Repaglinide Accord 0.5 mg tablet is white to off white, round, biconvex, with beveled edge, with inscription ‘R’ on one side and plain on other side.
Repaglinide Accord 0,5 mg tablete so belo sive, okrogle, izbočene s poševnim robom, brez prevleke in imajo na eni strani vtisnjen “R“ in na drugi so brez napisa.
The Repatha pre-filled pen is to be stored in the refrigerator (2°C to 8°C).
Napolnjen injekcijski peresnik zdravila Repatha mora biti shranjen v hladilniku (2-8 °C).
The Repatha pre-filled syringe is to be stored in the refrigerator (2°C to 8°C).
Napolnjena injekcijska brizga zdravila Repatha mora biti shranjena v hladilniku (2-8 °C).
The REPLACE-2 Trial (Patients undergoing PCI)
Študija REPLACE-2 (Bolniki, pri katerih se izvede PCI)
The replacement acts in same way as naturally produced interferon alfa.
Nadomestek deluje enako kot naravno proizvedeni interferon alfa.
The replacement acts in the same way as naturally produced G-CSF by encouraging the bone marrow to produce more white blood cells.
Nadomestek deluje enako kot naravno tvorjeni G-CSF, tako da spodbuja kostni mozeg k tvorjenju več belih krvničk.
The replacement anakinra acts in same way as the natural protein.
Nadomestna anakinra deluje enako kot naravna beljakovina.
The replacement enzyme helps to break down GL-3 and stops it building up in the patient’s cells.
Nadomestni encim pomaga razgraditi GL–3 in preprečiti njegovo kopičenje v celicah bolnika.
The replacement interferon beta-1a acts in the same way as naturally produced interferon beta.
Nadomestni interferon beta-1a deluje enako kot naravno proizvedeni interferon beta.
The replacement interferon beta-1b acts in the same way as naturally produced interferon beta.
Nadomestni interferon beta-1b deluje enako kot naravno proizvedeni interferon beta.
The replacement palifermin acts in the same way as naturally produced KGF.
Longmont, Colorado 80503 ZDA